The world’s largest ongoing HIV vaccine study has been expanded to consider multiple ways a vaccine might boost immune response to the AIDS virus. The U.S. Institute of Allergy and Infectious Diseases (NIAID) is testing the safety and efficacy of a dual vaccine candidate.
It’s called the HVTN 505 study and has been underway since June 2009. HVTN stands for the HIV Vaccine Trials Network, which is funded by the National Institutes of Health.
“The trial is being expanded both in terms of the number of participants, as well as what the trial is looking to
